Nykode Therapeutics ASA (NYKD) - Total Liabilities

Latest as of September 2025: Nkr6.45 Million NOK ≈ $678.20K USD

Based on the latest financial reports, Nykode Therapeutics ASA (NYKD) has total liabilities worth Nkr6.45 Million NOK (≈ $678.20K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore NYKD year-over-year net asset growth to track the company's year-over-year net asset growth rate.

Nykode Therapeutics ASA - Total Liabilities Trend (2016–2024)

This chart illustrates how Nykode Therapeutics ASA's total liabilities have evolved over time, based on quarterly financial data. See Nykode Therapeutics ASA free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Nykode Therapeutics ASA Competitors by Total Liabilities

The table below lists competitors of Nykode Therapeutics ASA ranked by their total liabilities.

Company	Country	Total Liabilities
Affluent Medical SAS PA:AFME	France	€38.73 Million
Caisse Régionale du Crédit Agricole Alpes Provence PA:CRAP	France	€23.14 Billion
Zevia Pbc NYSE:ZVIA	USA	$24.21 Million
Clarus Corp NASDAQ:CLAR	USA	$49.61 Million
Talga Group Ltd AU:TLG	Australia	AU$17.10 Million
Global Mediacom Tbk JK:BMTR	Indonesia	Rp6.59 Trillion
Tesoro Gold Ltd AU:TSO	Australia	AU$1.85 Million
GAMSUNG Corporation Co. Ltd KQ:036620	Korea	₩51.63 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down Nykode Therapeutics ASA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Nykode Therapeutics ASA (NYKD) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	170.98	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	16.37	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.06	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.01	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Nykode Therapeutics ASA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Nykode Therapeutics ASA (2016–2024)

The table below shows the annual total liabilities of Nykode Therapeutics ASA from 2016 to 2024.

Year	Total Liabilities	Change
2024-12-31	Nkr17.27 Million ≈ $1.82 Million	-53.24%
2023-12-31	Nkr36.93 Million ≈ $3.89 Million	-42.71%
2022-12-31	Nkr64.46 Million ≈ $6.78 Million	-9.85%
2021-12-31	Nkr71.50 Million ≈ $7.52 Million	+39.71%
2020-12-31	Nkr51.18 Million ≈ $5.39 Million	+1.30%
2019-12-31	Nkr50.52 Million ≈ $5.32 Million	+280.83%
2018-12-31	Nkr13.27 Million ≈ $1.40 Million	+21.29%
2017-12-31	Nkr10.94 Million ≈ $1.15 Million	+528.02%
2016-12-31	Nkr1.74 Million ≈ $183.26K	--

About Nykode Therapeutics ASA

OL:NYKD Norway Biotechnology

Market Cap

$110.30 Million

Nkr1.05 Billion NOK

Market Cap Rank

#18824 Global

#166 in Norway

Share Price

Nkr3.21

Change (1 day)

-5.03%

52-Week Range

Nkr1.47 - Nkr3.88

All Time High

Nkr91.25